Takeda Development Center Americas, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$38.2M
Doctors Paid
114
Transactions
5,787
2017 Total
$38.2M
Payment Breakdown by Category
Research$35.9M (94.1%)
Consulting$2.1M (5.5%)
Travel$109,517 (0.3%)
Food & Beverage$6,629 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $35.9M | 5,267 | 94.1% |
| Consulting Fee | $2.1M | 210 | 5.5% |
| Travel and Lodging | $109,517 | 143 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,807 | 23 | 0.0% |
| Food and Beverage | $6,629 | 144 | 0.0% |
Payments by Type
Research
$35.9M
5,267 transactions
General
$2.3M
520 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder | $8.9M | 0 | 867 |
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | $7.6M | 5 | 492 |
| Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Gout Subjects With Cardiovascular Comorbidities and Hyperuricemia | $4.0M | 6 | 1,219 |
| A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg-Day vs Paroxetine 20 mg-Day on Sexual Functioning in Healthy Subjects | $4.0M | 0 | 174 |
| A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment-Mild Alzheimer Disease | $1.5M | 0 | 6 |
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-week Study to Evaluate the Efficacy and Safety of Three Doses 5 mg,10 mg, 20 mg of Oral TAK-063 in Patients Acute SZC | $1.4M | 0 | 65 |
| P3 AC VDZ to ADA in UC N=658, 2 arms, US-EU | $1.1M | 0 | 386 |
| A prospective, observational, cohort safety study of vedolizumab for imflammatory disease | $867,634 | 0 | 207 |
| SC P3 CD Study | $841,476 | 0 | 243 |
| A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis ENTERPRET | $709,315 | 0 | 167 |
| Open-Label, Single-Arm, Multicenter, Prospective, Phase 4, Interventional, Flexible Dose Study to Evaluate the Effectiveness of Vortioxetine on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects | $685,167 | 0 | 208 |
| A Randomized, Double-Blind, Placebo-Controlled, Ascending Oral Single Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-418 in Healthy Subjects | $629,280 | 0 | 1 |
| A Randomized, Double-Blind, Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects with UC | $569,567 | 1 | 185 |
| A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors | $289,189 | 0 | 23 |
| A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Subcutaneous Vedolizumab in Patients with Ulcerative Colitis UC | $225,521 | 0 | 100 |
| A phase 2, randomized study of MLN0128 a dual TORC1-2 inhibitor, MLN0128 + MLN1117 a PI3Ka inhibitor, weekly paclitaxel, or the combination of weekly paclitaxel and MLN0128 in women with advanced, recurrent, or persistent endometrial cancer | $207,190 | 0 | 27 |
| A Phase 1b-2,Open-Label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced Clear-Cell Renal Cell Carcinoma That Has Progressed | $193,280 | 2 | 22 |
| An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohns Disease Treated With Vedolizumab IV | $179,313 | 0 | 61 |
| MCI Convertors from study 301 | $171,876 | 0 | 67 |
| TOURMALINE US MM-6 - A Phase 4,Open-Label,Single-Arm,Multicenter Study to Evaluate the Efficacy and Safety of IxazomibNINLAROin Combination with Lenalidomide and DexamethasoneIRDin Patients with Multiple Myeloma Previously Receiving a Bortezom | $160,956 | 2 | 7 |
| A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-Center Trial of Efficacy and Safety of Entyvio Vedolizumab in Subjects with Chronic Pouchitis | $134,891 | 0 | 16 |
| Safety and effecxtiveness of TAK-390MR in 1-11yr olds with symptomatice non-erosive GERD Treating heartburn associated with non-erosive GERD in children N=100, protocol under review | $116,839 | 0 | 18 |
| A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Toelrability and PK Study of Multiple Rising Doses of of MLN9708 for the Treatment of Subjects ith ISN-RPS Class III or IV Lupus Nephritis | $112,466 | 0 | 24 |
| A Phase 1b, Open-Label, Dose-Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel, in Patients with Solid Tumors | $107,586 | 0 | 9 |
| Safety and effectivness of TAK-390MR administered for 6 months to 1-11 yr olds with EE Healing, maintenance of healing & symptoms of endoscopy-proven EE in children N=60, protocol under review | $100,383 | 0 | 20 |
| An Open Label Phase 1 Two-Way Cross-Over Study of the | $79,572 | 0 | 9 |
| An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk | $74,258 | 0 | 67 |
| A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Efficacy of 2 Dose Regimens of Entyvio Vedolizumab in the Treatment of Fistulizing Crohns Disease | $73,157 | 0 | 10 |
| A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of MLN0002 in Patients with Ulcerative Colitis and Crohns Disease | $72,105 | 0 | 55 |
| Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas | $66,558 | 0 | 4 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Internal Medicine | $714,968 | 18 | $39,720 |
| Infectious Disease | $527,129 | 7 | $75,304 |
| Medical Oncology | $143,000 | 2 | $71,500 |
| Family Medicine | $140,255 | 1 | $140,255 |
| Hypertension Specialist | $134,901 | 1 | $134,901 |
| Neurology | $123,802 | 8 | $15,475 |
| Gastroenterology | $113,607 | 28 | $4,057 |
| Hematology & Oncology | $105,396 | 3 | $35,132 |
| Cardiovascular Disease | $102,552 | 5 | $20,510 |
| Psychiatry | $82,667 | 17 | $4,863 |
| Endocrinology, Diabetes & Metabolism | $68,303 | 3 | $22,768 |
| Geriatric Psychiatry | $59,792 | 2 | $29,896 |
| Psychosomatic Medicine | $32,686 | 1 | $32,686 |
| General Practice | $19,013 | 1 | $19,013 |
| Contractor | $15,850 | 1 | $15,850 |
| Neurological Surgery | $13,433 | 1 | $13,433 |
| Neurodevelopmental Disabilities | $1,754 | 1 | $1,754 |
| Gynecology | $1,639 | 1 | $1,639 |
| Rheumatology | $1,102 | 3 | $367.49 |
| Forensic Psychiatry | $163.71 | 1 | $163.71 |
| Specialist | $161.68 | 1 | $161.68 |
| Adult Reconstructive Orthopaedic Surgery | $96.45 | 1 | $96.45 |
| Transplant Hepatology | $80.83 | 1 | $80.83 |
| Geriatric Medicine | $69.46 | 1 | $69.46 |
| Pediatrics | $69.46 | 1 | $69.46 |
| Behavioral Neurology & Neuropsychiatry | $64.22 | 1 | $64.22 |
| Emergency Medical Services | $32.23 | 1 | $32.23 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Michael Mendelsohn, M.d, M.D | Internal Medicine | Boston, MA | $623,890 | $0 |
| Keith Gottesdiener, M.d, M.D | Infectious Disease | Rahway, NJ | $446,964 | $0 |
| Dr. David Han, M.d, M.D | Family Medicine | Glendale, CA | $140,255 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $134,901 | $0 |
| Ralph Boccia, M.d, M.D | Medical Oncology | Bethesda, MD | $94,680 | $0 |
| Mr. Ruemu Birhiray, Md, MD | Hematology & Oncology | Indianapolis, IN | $66,276 | $0 |
| Dr. Murray Raskind, Md, MD | Geriatric Psychiatry | Seattle, WA | $53,080 | $0 |
| John Hainsworth, Md, MD | Medical Oncology | Nashville, TN | $48,320 | $0 |
| Hakop Gevorkyan, Md, MD | Internal Medicine | Burbank, CA | $47,334 | $0 |
| Dr. Ronald Krall, Md, MD | Neurology | Steamboat Springs, CO | $46,690 | $0 |
| David Bennett, M.d, M.D | Neurology | Chicago, IL | $42,506 | $0 |
| Vivian Fonseca, Md, MD | Endocrinology, Diabetes & Metabolism | New Orleans, LA | $38,501 | $0 |
| Robert Chilton, Do, DO | Cardiovascular Disease | San Antonio, TX | $35,051 | $0 |
| Dr. Jeffrey Borer, Md, MD | Cardiovascular Disease | New York, NY | $33,788 | $0 |
| Dr. Haydn Thomas, M.d, M.D | Psychosomatic Medicine | Prairie Village, KS | $32,686 | $0 |
| Martin Farlow, Md, MD | Neurology | Indianapolis, IN | $32,580 | $0 |
| Sanjay Rajagopalan, Md, MD | Cardiovascular Disease | Baltimore, MD | $31,330 | $0 |
| Dr. Lev Gertsik, M.d, M.D | Psychiatry | South Pasadena, CA | $29,594 | $0 |
| Lon Schneider, Md, MD | Psychiatry | Los Angeles, CA | $24,210 | $0 |
| Jean-Frederic Colombel, M.d, M.D | Gastroenterology | New York, NY | $23,927 | $0 |
| Dr. Robert Edelman, M.d, M.D | Infectious Disease | Baltimore, MD | $23,097 | $0 |
| Dr. Robert Levine, Md, MD | Endocrinology, Diabetes & Metabolism | Guilford, CT | $23,052 | $0 |
| Unknown Provider | — | — | $21,916 | $0 |
| Bruce Booth, Md, MD | Hematology & Oncology | Newport News, VA | $21,000 | $0 |
| Dr. Donald Therasse, M.d, M.D | Infectious Disease | Zionsville, IN | $20,847 | $0 |
About Takeda Development Center Americas, Inc.
Takeda Development Center Americas, Inc. has made $38.2M in payments to 114 healthcare providers, recorded across 5,787 transactions in the CMS Open Payments database. In 2017, the company paid $38.2M. The top product by payment volume is Trintellix ($13.7M).
Payments were distributed across 27 medical specialties. The top specialty by payment amount is Internal Medicine ($714,968 to 18 doctors).
Payment categories include: Food & Beverage ($6,629), Consulting ($2.1M), Research ($35.9M), Travel & Lodging ($109,517).
Takeda Development Center Americas, Inc. is associated with 4 products in the CMS Open Payments database, including Actos, Uloric, and Dexilant.